Accessibility Menu
 
Dr. Reddy's Laboratories logo

Dr. Reddy's Laboratories

(NYSE) RDY

Current Price$13.76
Market Cap$11.46B
Since IPO (2001)+1,501%
5 Year+15%
1 Year+4%
1 Month-7%

Dr. Reddy's Laboratories Financials at a Glance

Market Cap

$11.46B

Revenue (TTM)

$345.83B

Net Income (TTM)

$56.59B

EPS (TTM)

$0.78

P/E Ratio

17.67

Dividend

$0.09

Beta (Volatility)

0.42 (Low)

Price

$13.76

Volume

42,847

Open

$13.66

Previous Close

$13.76

Daily Range

$13.66 - $13.94

52-Week Range

$12.26 - $16.17

RDY: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dr. Reddy's Laboratories

Industry

Pharmaceuticals

Employees

27,811

CEO

Erez Israeli, MBA

Headquarters

Hyderabad, 500034, IN

RDY Financials

Key Financial Metrics (TTM)

Gross Margin

55%

Operating Margin

19%

Net Income Margin

16%

Return on Equity

18%

Return on Capital

17%

Return on Assets

10%

Earnings Yield

5.66%

Dividend Yield

0.01%

Payout Ratio

11.77%

Stock Overview

Market Cap

$11.46B

Shares Outstanding

832.39M

Volume

42.85K

Short Interest

0.00%

Avg. Volume

1.95M

Financials (TTM)

Gross Profit

$190.43B

Operating Income

$71.84B

EBITDA

$96.67B

Operating Cash Flow

$46.43B

Capital Expenditure

$34.40B

Free Cash Flow

$12.03B

Cash & ST Invst.

$57.91B

Total Debt

$46.77B

Dr. Reddy's Laboratories Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$87.27B

+4.4%

Gross Profit

$46.81B

-4.6%

Gross Margin

53.63%

N/A

Market Cap

$11.46B

N/A

Market Cap/Employee

$423.77K

N/A

Employees

27,048

N/A

Net Income

$12.10B

-14.4%

EBITDA

$19.56B

-19.4%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Net Cash

$14.86B

+83.6%

Accounts Receivable

$124.27B

+11.5%

Inventory

$79.01B

+10.3%

Long Term Debt

$11.61B

+53.2%

Short Term Debt

$56.12B

+29.0%

Return on Assets

10.05%

N/A

Return on Invested Capital

16.53%

N/A

Free Cash Flow

$3.59B

+263.2%

Operating Cash Flow

$10.91B

+64.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EXELExelixis, Inc.
$42.36-0.99%
SOLVSolventum Corporation
$64.71+0.11%
ENSGThe Ensign Group, Inc.
$201.99-0.93%
ELANElanco Animal Health Incorporated
$24.58-3.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$171.28-0.04%
NOKNokia
$8.28-0.02%
NFLXNetflix
$93.32+0.01%
INTCIntel
$44.09-0.07%

Questions About RDY

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.